Results 131 to 140 of about 1,443,667 (357)

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody

Cancer Management and Research, 2023
Darren Pan, Joshua Richter Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USACorrespondence: Darren Pan, One Gustave L.
Pan D, Richter J
doaj  

BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells

Translational Oncology, 2017
Among different cancer immunotherapy approaches, bispecific antibodies (BsAbs) are of great interest due to their ability to recruit immune cells to kill tumor cells directly.
Jieyu Xing, Limin Lin, Jing Li, Jiayu Liu, Changhua Zhou, Haitao Pan, Rui Shu, Bin Dong, Donglin Cao, Qing Li, Zhong Wang   +10 more
doaj   +1 more source

Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. [PDF]

, 1993
Louis M. Weiner, Michele Holmes, A Richeson, Antony Godwin, Gregory P. Adams, Sylvia T. Hsieh-Ma, David B. Ring, R. Katherine Alpaugh   +7 more
openalex   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

iScience
Summary: A current challenge is the emergence of SARS-CoV-2 variants, such as BQ.1.1 and XBB.1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness. Emergency-use antibody drugs, including the widely effective bebtelovimab, are
Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, Yuko Okemoto-Nakamura, Yoshimi Shimizu, Motohiko Ogawa, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Mika K. Kaneko, Masayoshi Fukasawa, Yukinari Kato, Kohji Noguchi   +12 more
doaj  

Anti-CD3:anti-IL-2 receptor bispecific monoclonal antibody. Targeting of activated T cells in vitro. [PDF]

, 1993
James A. MacLean, Zhen Su, Y. Guo, M S Sy, R B Colvin, Johnson T. Wong   +5 more
openalex   +1 more source

The evolution of bispecific antibodies [PDF]

Expert Opinion on Biological Therapy, 2022
openaire   +2 more sources

A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Cytokine release syndrome (CRS) is a common, acute adverse event associated with T‐cell redirecting therapies such as bispecific antibodies (BsAbs). The nature of CRS events data makes it challenging to capture an unbiased exposure–response relationship with commonly used models.
Donald Irby, Jennifer Hibma, Mohamed Elmeliegy, Diane Wang, Erik Vandendries, Kamrine Poels, Blerta Shtylla, Jason H. Williams   +7 more
wiley   +1 more source

Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. [PDF]

, 1991
Jan Brissinck, C. Demanet, M. Moser, Oberdan Léo, K Thielemans   +4 more
openalex   +1 more source

IQ Survey Results on Current Industry Practices—Part 1: Immunogenicity Risk Assessment

Clinical Pharmacology &Therapeutics, EarlyView.
An immunogenicity risk assessment (IRA) is a relatively new expectation of health authorities that is increasingly incorporated into the drug development process across the pharmaceutical/biotech industry. The guiding principle for an IRA includes a comprehensive evaluation of product‐ and patient‐related factors that may influence the immunogenic ...
Christine Grimaldi, Susan Richards, Daniel Baltrukonis, Shelley Sims Belouski, Kelly Coble, Sanjay L. Dholakiya, Joanna Grudzinska‐Goebel, Gerry Kolaitis, Jocelyn H. Leu, Linlin Luo, Stephen Lowe, Tao Niu, Henrik Toft‐Hansen, Jianning Yang, Benjamin Wu   +14 more
wiley   +1 more source